Your browser doesn't support javascript.
loading
p21 produces a bioactive secretome that places stressed cells under immunosurveillance.
Sturmlechner, Ines; Zhang, Cheng; Sine, Chance C; van Deursen, Erik-Jan; Jeganathan, Karthik B; Hamada, Naomi; Grasic, Jan; Friedman, David; Stutchman, Jeremy T; Can, Ismail; Hamada, Masakazu; Lim, Do Young; Lee, Jeong-Heon; Ordog, Tamas; Laberge, Remi-Martin; Shapiro, Virginia; Baker, Darren J; Li, Hu; van Deursen, Jan M.
Affiliation
  • Sturmlechner I; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
  • Zhang C; Department of Pediatrics, Molecular Genetics Section, University of Groningen, University Medical Center Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, Netherlands.
  • Sine CC; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
  • van Deursen EJ; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
  • Jeganathan KB; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
  • Hamada N; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
  • Grasic J; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
  • Friedman D; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
  • Stutchman JT; Department of Immunology, Mayo Clinic, Rochester, MN, USA.
  • Can I; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
  • Hamada M; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
  • Lim DY; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
  • Lee JH; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
  • Ordog T; Epigenomics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
  • Laberge RM; Epigenomics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
  • Shapiro V; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA.
  • Baker DJ; Unity Biotechnology, South San Francisco, CA 94080, USA.
  • Li H; Department of Immunology, Mayo Clinic, Rochester, MN, USA.
  • van Deursen JM; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
Science ; 374(6567): eabb3420, 2021 Oct 29.
Article in En | MEDLINE | ID: mdl-34709885
ABSTRACT
Immune cells identify and destroy damaged cells to prevent them from causing cancer or other pathologies by mechanisms that remain poorly understood. Here, we report that the cell-cycle inhibitor p21 places cells under immunosurveillance to establish a biological timer mechanism that controls cell fate. p21 activates retinoblastoma protein (Rb)­dependent transcription at select gene promoters to generate a complex bioactive secretome, termed p21-activated secretory phenotype (PASP). The PASP includes the chemokine CXCL14, which promptly attracts macrophages. These macrophages disengage if cells normalize p21 within 4 days, but if p21 induction persists, they polarize toward an M1 phenotype and lymphocytes mount a cytotoxic T cell response to eliminate target cells, including preneoplastic cells. Thus, p21 concurrently induces proliferative arrest and immunosurveillance of cells under duress.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cellular Senescence / Cyclin-Dependent Kinase Inhibitor p21 / Immunologic Surveillance Limits: Animals / Humans Language: En Journal: Science Year: 2021 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cellular Senescence / Cyclin-Dependent Kinase Inhibitor p21 / Immunologic Surveillance Limits: Animals / Humans Language: En Journal: Science Year: 2021 Document type: Article Affiliation country: Estados Unidos